Pfizer and Adaptive Biotechnologies have entered into a translational research collaboration to leverage next gen sequencing of the adaptive immune system to advance Pfizer’s immuno-oncology pipeline. The companies will combine drug development and platform technology biomarker expertise to identify patients who may benefit from immunotherapy. Adaptive’s immunosequencing platform measures the patient’s immune-cell repertoire, providing a translational tool to accelerate Pfizer’s immuno-oncol...